Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 62 for “"Ivacaftor"”.
-
Burden of Illness and Pharmacoeconomic Evaluation of Lumacaftor/Ivacaftor in Cystic Fibrosis
… a pharmacoeconomic evaluation of lumacaftor/ivacaftor in the treatment of CF. <strong></strong></p> <p><strong>Methods:</strong> The study was conducted in two parts. Part 1 involved a retrospective analysis using individuals in MEPS database with an International Classification of Diseases, …
-
Ο ρόλος του Kalydeco (Ivacaftor) στην αντιμετώπιση της κυστικής ίνωσης: Συστηματική ανασκόπηση
… 2012 για το φάρμακο κυστικής ίνωσης Kalydeco® (Ivacaftor), σηματοδότησε μια σημαντική πρόοδο στη θεραπεία της ΚΙ, διότι πρόκειται για το πρώτο φάρμακο που στοχεύει στο μηχανισμό της νόσου και όχι στα συμπτώματά της. Με βάση τα προαναφερόμενα, η συγκεκριμένη εργασία μελετάει τα παραπάνω, τόσο …
-
Dynamical Effects of Mutations and Ivacaftor Binding on the Cystic Fibrosis Transmembrane Conductance Regulator
… small-molecule modulators, such as potentiators (ivacaftor) and correctors (lumacaftor, tezacaftor), have improved clinical outcomes, they often only partially restore CFTR function, and the precise atomistic mechanisms underlying their effects remain unclear.<br/>In this thesis, I employed …
-
Nutritional and Metabolic Effects of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis
… CF population. Recently Elexacaftor/Tezacaftor/Ivacaftor (ETI) was approved for use in up to 90% of people with CF. Our single center open-label observational cohort study aimed to explore the changes in dietary and metabolic outcomes with use of ETI. Methods: Participants underwent baseline …
-
Clinical outcomes of real-world Kalydeco (ivacaftor); Cork study - understanding the implications of CFTR modulation
… consequences of CFTR dysfunction. The advent of ivacaftor offers the opportunity to evaluate the effect of restoration of CFTR function on CF lung disease and extrapulmonary manifestations. Global prevalence of the G551D mutation is 4%. Prevalance at Cork CF centre is 23%. Thus this work …
-
The Investigation of Quality of Life, Perceived Disease Severity, and Adherence in Patients with the G551D Mutation Receiving Ivacaftor Therapy
… to three times a day for up to 20 minutes each. Ivacaftor is a new oral cystic fibrosis therapy for the treatment of CF approved specifically for patients with the G551D mutation in January of 2012, and is only available to fewer than 5% of the total CF population. Although this type of therapy …
-
Elexacaftor/Tezacaftor/Ivacaftor Prescription in Lung Transplant Recipients with Cystic Fibrosis in the US: A CFF Patient Registry Cross-Sectional Analysis
Elexacaftor/tezacaftor/ivacaftor (ETI) has dramatically improved pulmonary and extrapulmonary manifestations of cystic fibrosis (CF). ETI clinical trials excluded lung transplant (LTx) recipients, and current post-transplant prescribing practices are not evidence-based. We sought to identify the …
-
New treatment options for cystic fibrosis
… disease processes. Three drugs, including ivacaftor, which has been approved by the United States Food and Drug Administration, and VX-809 and ataluren, which are still in clinical trial, have been shown to improve patient clinical measures. VX-809 targets the most prevalent CF mutation, …
-
Exploiting Species Differences to Understand the Function and Pharmacology of the Cystic Fibrosis Transmembrane Conductance Regulator
… channel. The licensing of the CFTR potentiator ivacaftor (VX-770, Vertex Pharmaceuticals Inc.), provided proof of concept for the use of small molecules to treat CF. However, the mechanism of action of ivacaftor is not well understood. Studies exploiting species differences in CFTR pharmacology …
-
Η αξία της δοκιμασίας ιδρώτα στη μέτρηση της λειτουργικότητας της πρωτεΐνης CFTR στην κυστική ίνωση: Μια συστηματική ανασκόπηση
… δικτύου, το vanzacaftor/tezacaftor/deutivacaftor επέφερε τη μεγαλύτερη μείωση χλωρίου (μέση διαφορά [MD] −51,78 mmol/L, 95% CI −60,23 έως −43,34, P-score 0,99), ακολουθούμενο από το elexacaftor/tezacaftor/ivacaftor (MD −46,18, −52,39 έως −39,98, 0,80), το ivacaftor (MD −35,42, 0,60) και …
-
Influencia de la detección fúngica en las exacerbaciones de los pacientes con Fibrosis quística y evolución tras la introducción de Elexacaftor/Tezacaftor/Ivacaftor
… tras la introducción de Elexacaftor/Tezacaftor /Ivacaftor (ETI).Material y métodos: Se diseñó un estudio prospectivo en pacientes adultos (> 18 años) en seguimiento en la Unidad de FQ del Hospital Universitario Central de Asturias (HUCA), entre enero de 2021 y abril de 2022, con al menos una …
-
Utilisation of CFTR orthologues to evaluate new therapies for cystic fibrosis
… combination therapy elexacaftor-tezacaftor-ivacaftor was applied to heterologous cells. When compared with rescue by low temperature incubation, elexacaftor-tezacaftor-ivacaftor increased current flow through the channel and improved the thermostability of a sub-population of channels …
-
Νεότερα φάρμακα για τη θεραπεία της κυστικής ίνωσης
… Στην κλινική πράξη χρησιμοποιούνται, ο ενισχυτής Ivacaftor, σε παιδιά ≥ 4 μηνών με συγκεκριμένες μεταλλάξεις, ο συνδυασμός επιδιορθωτή με ενισχυτή Lumacaftor/Ivacaftor για ασθενείς ομοζυγώτες για την Phe508del ≥ 12 μηνών, ο 2ος συνδυασμός επιδιορθωτή με ενισχυτή Tezacaftor/Ivacaftor για παιδιά ≥ 6 …
-
Using registry data to estimate the effects of long-term treatment use in cystic fibrosis
… by investigating two CF treatments: DNase and ivacaftor. DNase is a common CF treatment and generally, once started, it continues to be used indefinitely. Despite this, no studies have investigated its long-term effects. Estimating these effects using registry data is difficult due to …
-
A mixed methods study in cystic fibrosis following the widespread availability of elexacaftor/tezacaftor/ivacaftor. Understanding the impact of context change in long-term condition care
… how the introduction of elexacaftor/tezacaftor/ivacaftor (ETI) has shaped cystic fibrosis (CF) care. This pragmatic, mixed-methods Realist Evaluation examined how clinicians and people with CF (pwCF) made sense of and responded to this contextual change, focussing on adherence to inhaled …
-
Regulation of CFTR function and stability by phosphorylation and its membrane environment
… CFTR function. Potentiator drugs, like ivacaftor, enhance CFTR function at the cell surface. I conducted biochemical experiments to find that high concentrations of ivacaftor non-specifically destabilized F508del-CFTR and other membrane proteins. This non-specific destabilization of …
-
Remodelado óseo en los pacientes con fibrosis quística en tratamiento con moduladores del canal regulador de la conductancia transmembrana
… con moduladores del CFTR: lumacafator-ivacaftor (LUM/IVA), tezacaftor-ivacaftor (TEZ/IVA) o elexacaftor-tezacaftor-ivacaftor (ETI). Metodología: Estudio observacional prospectivo con evaluación basal y al año del tratamiento. Se midieron DMO en columna lumbar, cadera y cuello femoral …
-
Role of the Lipid Environment and Cholesterol Content in the Function of CFTR Modulators
… evaluated the effects of two CFTR modulators - Ivacaftor and Lumacaftor (and their combination, Orkambi) - on the folding of mutant CFTR hairpins, with a focus on whether these drugs can rescue the fold of the hairpins to the WT conformation. Finally, to gauge the importance of the membrane …
Page 1 of 4